advanced prostate cancer treatment

Dr David Wong treats Wesley Medical Imaging’s first Lutetium 177 PSMA Therapy patient, Robert Marsh.

Uniting Care Medical Imaging completed the first Queensland Lutetium 177 PSMA Therapy non-invasive advanced prostate cancer treatment at its Wesley Medical Imaging clinic on 10 August 2017.

It is the only facility (both public and private) offering this clinical treatment in Queensland, and there are only a handful of other Australian treatment centres, although some public facilities are establishing trials.

About Lutetium 177 PSMA Therapy

Pioneered in Germany in the last 5 years, Lutetium 177 PSMA Therapy or Prostate-Specific Membrane Antigen Therapy is increasingly being used for men with advanced prostate cancer. This non-invasive advanced prostate cancer treatment aims to reduce the size of the tumour/s and stop them from multiplying, as well as to ease the symptoms that people may get with these tumours. In the majority of cases, Lutetium 177 PSMA therapy stabilises or improves disease that has previously been progressive, and some patients achieve remission.

Treatment at UCMI

Dr David Wong, Director of the Advanced PET and Nuclear Medicine Centre at Wesley Medical Imaging, and Associate Professor with the Centre for Advanced Imaging at the University of Queensland, travelled to Germany to learn the treatment. In addition, David was instrumental in the performance of the first Ga68 PSMA PET CT diagnostic study in men with prostate cancer in Australia on 16 July 2014. Dr Wong is positive about the therapy.

“At the very least, this therapy offers a credible addition to the treatment of advanced prostate cancer in men. Lutetium 177 PSMA therapy was described in a Financial Review story in October 2016 as a ‘game-changing’ nuclear treatment for prostate cancer

First Queensland Patient

Wesley Medical Imaging patient, Robert Marsh, has received Lutetium 117 PSMA therapy treatment as part of his ongoing battle with advanced prostate cancer.

“After undergoing radiation treatment for my prostate cancer, then three years of the drug Zoladex, unfortunately my PSA rose.”

Prostate-specific antigen, or PSA, is a protein produced by cells of the prostate gland. The PSA test measures the level of PSA in a man’s blood.

“At this stage my options were becoming limited, but after researching Lutetium therapy and discussing it with my oncologist, I was ecstatic to discover that Assoc.Prof Wong at Wesley Medical Imaging could offer the treatment.”

To date following the treatment Robert has suffered no side effects.

For more information about Lutetium 177 PSMA Therapy non-invasive advanced prostate cancer treatment, contact Wesley Medical Imaging.